Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide for Mild or Moderate COVID-19 in High-Risk Patients
NCT05157243Phase 3Withdrawn
- Sponsor
- Romark Laboratories
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of nitazoxanide in coronavirus disease 2019 (COVID-19), sponsored by Romark Laboratories. Planned start Aug 2024; status: withdrawn.
02
Drugs
nitazoxanide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05157243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157243.